

Clinical Oncology



Coordinator

Barnadas Molins, Agustí FGS
 abarnadasm@santpau.cat

Members

Alfonso Ruiz, Rosa	IR
Andrés Granyo, Marta	IR
Arqueros Núñez, Cristina	FGS
Barba Joaquín, Andrés	IR
Bell Ramírez, Olga Lidia	IR
Buxó Orra, Elvira	FGS
Calvo Vergés, Núria	FGS
Casanova Bombardo, Clàudia	IR
Castells Tello, Diana	IR
Escuín Borràs, Daniel	IR
Fisas Masferrer, David	IR
Galceran Gallagher, Sara	IR
Gallego Rubio, Óscar Salvador	FGS
García Belinchon, Mercè	IR
Gisbert Beamud, Alexandra	IR
Lavernía Rosell, Laia	IR
Lladó Jordan, Gina	IR
Llobet Busquets, Mireia	IR
López Pousa, Antonio	FGS
Majem Tarruella, Margarita	FGS
Maroto Rey, José Pablo	FGS
Martín Lorente, Cristina	FGS
Martín Richard, Marta	FGS
Menéndez Cuervo, Dulce Maria	IR
Paez López-Bravo, David	FGS
Pallarès Curto, Maria Cinta	FGS
Pich Martínez, Olga	IR
Ramon y Cajal Asensio, Teresa	FGS
Ribas Carbonell, Romina	IR
Roca Gimeno, Llara	IR
Roca Solà, Marc	IR
Saavedra Bandera, Eduard	IR
Sebio Garcia, Ana	FGS
Serra López, Jorgina	IR
Tibau i Martorell, Ariadna	FGS
Tijeras Pérez, Sandra	IR
Tobeña Puyal, María	FGS
Virgili Manrique, Anna Cristina	IR

Main Lines of Research

Clinical

- ▶ Development of new therapeutic strategies.
- ▶ Studies to improve tumour staging.
- ▶ Studies to detect residual disease.

Translational

- ▶ Personalized anticancer therapy.
- ▶ Studies of predictive and prognostic molecular markers.

Challenges

- ▶ Consolidate clinical research into cancer.
- ▶ Foster translational research into cancer in cooperation with other internal and external research groups.
- ▶ Consolidate the bank of tumours, DNA and serum for patients with cancer diagnosed and treated in our hospital.
- ▶ Develop new early-stage drugs (phase 0/1 studies).

Collaborations

Collaborations with other IIB Sant Pau Groups

- ▶ Oncogenesis and Antitumour Drugs (Dr. Ramon Mangues).
- ▶ Molecular Pathology of Urologic Cancer (Dr. F Algaba)
- ▶ Genetic Diseases (Dr. Montserrat Baiget).

- ▶ Breast Cancer (Dr. E Lerma).

External Collaborations

- ▶ Tumoural progression modelling group at the Biomedical Research Institute (IRB) (Dr. A. Nebreda).
- ▶ Methylation and resistance to chemotherapy in ovarian cancer (Dr. M. Esteller).

Active Grants

- ▶ Daniel Escuín Borràs. Perfil de expresión de miRNAs en tumor primario de mama y sus ganglios linfáticos centinela: implicaciones en los mecanismos de invasión y su valor como marcadores metastásicos. PI13/00110. Instituto de Salud Carlos III. Duration: 2014-2018. 76,000.00 €.
- ▶ David Paez López-Bravo. La familia de los receptores tirosina kinasa ERBB y sus mecanismos reguladores: Identificación mediante NGS de variantes genéticas asociadas a las respuestas excepcionales a las terapias biológicas en cáncer colorrectal. AECC 2015-1. Asociación Española Contra el Cáncer. Duration: 2016-2018. 20,000.00 €.
- ▶ Georgia Anguera Palacios. Identificación de mutaciones que confieren sensibilidad a inhibidores de mTOR en Carcinoma renal de células cromóforas (chRCC), mediante estrategia de casos extremos. SOGUG 2015-2016. Grupo Español de Tratamiento de Tumores Urológicos. Duration: 2015-2017. 18,181.82 €.
- ▶ Anna Cristina Virgili Manrique. Marcadores de células madre embrionarias y mesenquimales en la predicción de respuesta al tratamiento en sarcomas de tejidos blandos de alto riesgo. IR16-R3. Fundació Privada Hospital de la Santa Creu i Sant Pau. Duration: 2016-2017. 35,500.00 €.
- ▶ Margarita Majem Tarruella. Maneig dels pacients amb càncer de pulmó. IR16-E1. Fundació Privada Hospital de la Santa Creu i Sant Pau. Duration: 2017-2017. 2,200.00 €.
- ▶ Ana Sebio Garcia. Estancia para la investigación clínica y traslacional en la Unidad de Sarcomas del Hospital Royal Marsden de Londres. MV16/00043. Instituto de Salud Carlos III. Duration: 2017-2017. 8,000.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

Grants Awarded in 2017

- ▶ Ana Sebio Garcia. Evaluación de las alteraciones de la distrofina y proteínas afines como factores pronósticos en pacientes afectos de leiomiomas. PI17/00143. Instituto de Salud Carlos III. Duration: 2018-2020. 61,500.00 €.

Note: Total amount granted to PI. It does not include indirect costs.

- Ivana Sullivan. Pharmacogenetic studies and prognostic factors in non-small cell lung cancer. Universitat Autònoma de Barcelona. Directors: Agustí Barnadas Molins, Juliana Salazar Blanco. Date of defense: 22/09/2017.

*TIF: 351.635 **MIF: 7.0327

Aapro M., De Laurentiis M., Rea D., Bargallo Rocha J.E., Elizalde R., Landherr L., Linderholm B., Mamounas E., Markopoulos C., Neven P., Petrovsky A., Rouzier R., Smit V., Svedman C., Schneider D., Thomssen C., Martin M., The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2-) breast cancer: When might multi-gene assays be of value? (2017) *BREAST*, 33, 191-199.

IF: 2.951

Arqueros C., Salazar J., Arranz M.J., Sebio A., Mora J., Sullivan I., Tobena M., Martin-Richard M., Barnadas A., Baiget M., Paez D., SPARC gene variants predict clinical outcome in locally advanced and metastatic pancreatic cancer patients (2017) *MED ONCOL*, 34 (8).

IF: 2.920

Balana C., Capellades J., Pineda E., Estival A., Puig J., Domenech S., Verger E., Pujol T., Martinez-Garcia M., Oleaga L., Velarde J., Mesia C., Fuentes R., Marruecos J., Del Barco S., Villa S., Carrato C., Gallego O., Gil-Gil M., Craven-Bartle J., Alameda F., Pseudoprogression as an adverse event of glioblastoma therapy (2017) *CANCER MED-US*, 6 (12), 2858-2866.

IF: 3.202

Ballesteros M., Montero N., Lopez-Pousa A., Urrutia G., Sola I., Rada G., Pardo-Hernandez H., Bonfill X., Evidence mapping based on systematic reviews of therapeutic interventions for gastrointestinal stromal tumors (GIST) (2017) *BMC MED RES METHODOL*, 17 (1).

IF: 2.524

Buonadonna A., Benson C., Casanova J., Kasper B., Lopez Pousa A., Mazzeo F., Brodowicz T., Penel N., A noninterventional, multicenter, prospective phase IV study of trabectedin in patients with advanced soft tissue sarcoma (2017) *ANTI-CANCER DRUG*, 28 (10), 1157-1165.

IF: 1.869

Calvete O., Garcia-Pavia P., Dominguez F., Bougeard G., Kunze K., Braeuninger A., Teule A., Lasa A., Ramon Y Cajal T., Lloret G., Fernandez V., Lazaro C., Urioste M., Benitez J., The wide spectrum of POT1 gene variants correlates with multiple cancer types (2017) *EUR J HUM GENET*, 25 (11), 1278-1281.

IF: 3.636

Capdevila J., Galofre J.C., Grande E., Zafon Llopias C., Ramon Y Cajal Asensio T., Navarro Gonzalez E., Jimenez-Fonseca P., Santamaria Sandi J., Gomez Saez J.M., Riesco Eizaguirre G., Consensus on the management of ad-

vanced radioactive iodine-refractory differentiated thyroid cancer on behalf of the Spanish Society of Endocrinology Thyroid Cancer Working Group (GTSEEN) and Spanish Rare Cancer Working Group (GETHI) (2017) *CLIN TRANSL ONCOL*, 19 (3), 279-287.

IF: 2.392

Capdevila J., Trigo J.M., Aller J., Manzano J.L., Adrian S.G., Llopias C.Z., Reig O., Bohn U., Cajal T.R.Y., Duran-Poveda M., Astorga B.G., Lopez-Alfonso A., Martinez J.M., Porras I., Reina J.J., Palacios N., Grande E., Cillan E., Matos I., Grau J.J., Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC) (2017) *EUR J ENDOCRINOL*, 177 (4), 309-317.

IF: 4.333

Casali P.G., Fumagalli E., Gronchi A., Zalberg J., Kotasek D., Cesne A.L., Blay J.-Y., Italiano A., Reichardt P., Lindner L.H., Grunwald V., Judson I.R., Van Der Graaf W., Schoffski P., Litiere S., Marreaud S., Leyvraz S., Pousa A.L., Sleijfer S., Verweij J., Kerst J.M., Hogendoorn P., Van Der Graaf W., Rutkowski P., Ten-year progression-free and overall survival in patients with unresectable or metastatic GI stromal tumors: Long-term analysis of the european organisation for research and treatment of cancer, Italian sarcoma group, and Australasian gastrointestinal trials group intergroup phase III randomized trial on imatinib at two dose levels (2017) *J CLIN ONCOL*, 35 (15), 1713-1720.

IF: 26.303

Cinieri S., Chan A., Altundag K., Vandebroek A., Tubiana-Mathieu N., Barnadas A., Dodyk P., Lazzarelli S., Botha M., Rauch D., Villanova G., Coskun U., Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer (2017) *CLIN BREAST CANCER*, 17 (2), 91-99.e1.

IF: 2.703

Codony-Servat J., Cuatrecasas M., Asensio E., Montironi C., Martinez-Cardus A., Marin-Aguilera M., Horndler C., Martinez-Balibrea E., Rubini M., Jares P., Reig O., Victoria I., Gaba L., Martin-Richard M., Alonso V., Escudero P., Fernandez-Martos C., Feliu J., Mendez J.C., Mendez M., Gallego J., Salud A., Rojo F., Castells A., Prat A., Rosell R., Garcia-Albeniz X., Camps J., Maurel J., Nuclear IGF-1R predicts chemotherapy and targeted therapy resis-

tance in metastatic colorectal cancer (2017) *BRIT J CANCER*, 117 (12), 1777-1786.

IF: 5.922

de Castro J., Gonzalez-Larriba J.L., Vazquez S., Massuti B., Sanchez-Torres J.M., Domine M., Garrido P., Calles A., Artal A., Collado R., Garcia R., Sereno M., Majem M., Macias J.A., Juan O., Gomez-Codina J., Hernandez B., Lazaro M., Ortega A.L., Cobo M., Trigo J.M., Carcereny E., Rolfó C., Macia S., Munoz J., Diz P., Mendez M., Rosillo F., Paz-Ares L., Cardona J.V., Isla D., Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy (2017) *CLIN TRANSL ONCOL*, 19 (2), 219-226.

IF: 2.392

Duran I., Lambea J., Maroto P., Gonzalez-Larriba J.L., Flores L., Granados-Principal S., Graupera M., Saez B., Vivancos A., Casanovas O., Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action (2017) *TARGET ONCOL*, 12 (1), 19-35.

IF: 3.877

Echavarria I., Lopez-Tarruella S., Marquez-Rodas I., Jerez Y., Martin M., Neratinib for the treatment of HER2-positive early stage breast cancer (2017) *EXPERT REV ANTICANC*, 17 (8), 669-679.

IF: 2.347

Fischer S., Tandstad T., Wheeler M., Porfiri E., Flechon A., Aparicio J., Klingbiel D., Skrbinc B., Basso U., Shamash J., Lorch A., Dieckmann K.-P., Cohn-Cedermark G., Stahl O., Chau C., Arriola E., Marti K., Hutton P., Laguerre B., Maroto P., Beyer J., Gillissen S., Outcome of men with relapse after adjuvant carboplatin for clinical stage I seminoma (2017) *J CLIN ONCOL*, 35 (2), 194-200.

IF: 26.303

Gonzalez A., Lluch A., Aba E., Albanell J., Anton A., Alvarez I., Ayala F., Barnadas A., Calvo L., Ciruelos E., Cortes J., de la Haba J., Lopez-Vega J.M., Martinez E., Munoz M., Pelaez I., Redondo A., Rodriguez A., Rodriguez C.A., Ruiz A., Llobat A., A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM) (2017) *CLIN TRANSL ONCOL*, 19 (5), 616-624.

IF: 2.392

Gonzalez del Alba A., Arranz J.A., Puente J., Mendez-Vidal M.J., Gallardo E., Grande E., Perez-Valderrama B., Gonzalez-Billalabeitia E., Lazaro-Quintela M., Pinto A., Lainez N.,